Back to news

Telomir Pharmaceuticals Selects Linical to Advance FDA-Cleared Phase 1/2 Clinical Trial of Telomir-Zn in Triple-Negative Breast Cancer

Globe Newswire•18/11/2026•08:00 ET
0

Key Highlights

  • ➤Telomir (TELO) selects Linical to support FDA-cleared Phase 1/2 TNBC trial
  • ➤Clinical trial agreements executed, targeting initiation in the first quarter of 2027
  • ➤Telomir-Zn trial will evaluate safety, pharmacokinetics, and preliminary antitumor activity
  • ➤Linical brings more than two decades of oncology clinical-development experience

Expert Statements

Erez Aminov, Chairman and Chief Executive Officer of Telomir Pharmaceuticals

“Following FDA clearance of our IND, our priority has been to establish the clinical infrastructure necessary to advance Telomir-Zn into patients”

Erez Aminov, Chairman and Chief Executive Officer of Telomir Pharmaceuticals

“We selected Linical for its extensive oncology experience, including breast cancer and early-phase clinical development.”

Erez Aminov, Chairman and Chief Executive Officer of Telomir Pharmaceuticals

“With our clinical trial agreements now executed, we are focused on advancing toward clinical initiation in the first quarter of 2027 and evaluating the potential of our novel oral epigenetic therapy in patients with triple-negative breast cancer.”

Clareece West, President at Linical

“We are pleased to partner with Telomir Pharmaceuticals as it prepares to evaluate Telomir-Zn in patients with triple-negative breast cancer”

Clareece West, President at Linical

“Our CRO team brings extensive experience in oncology and early-phase clinical development to this partnership, and we look forward to helping Telomir advance their important clinical program.”

Global CRO Brings Extensive Oncology Experience, Including Breast Cancer and Early-Phase Clinical Development

Executed Clinical Trial Agreements Support Targeted Clinical Initiation in the First Quarter of 2027

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in